Medium Risk

Syncom Formulations (India) Limited

Development, manufacturing & sale of pharmaceutical products

CIN: L24239MH1988PLC047759 FY: - Revenue: ₹462.8 Cr
5.5
ESG Risk
Score /10
Compliance RiskEpr ExposureGovernance Risk

Risk Breakdown

GHG Intensity
5.0
Water Intensity
5.0
Waste Intensity
1.0
EPR Exposure
6.5
Compliance Risk
10.0
HR Risk
5.0
Governance Risk
6.0

Financial Exposure

Est. Compliance Cost₹1–3 crore
EPR ApplicableUnknown
Scope 1 Emissions— tCO2e
Scope 2 Emissions— tCO2e
Water Withdrawal— m³
Waste Generated0.8 T

Governance

Anti-Corruption PolicyUnknown
Conflict of Interest PolicyYes
BRSR AssuranceNone
Assurance Provider

Double Materiality

Financial Materiality5.5
Impact Materiality5.1
QuadrantDual Materiality

Supply Chain

MSME Sourcing0.2%
Lifecycle AssessmentNo
Product ReclaimYes

Material Risks

e-waste

AI Risk Summary

**Financial Risk Summary – Syncom Formulations (India) Limited** Syncom's largest financial exposure stems from critical compliance gaps: a perfect 10.0/10 compliance risk score with estimated remediation costs of ₹1–3 crore, compounded by high EPR (Extended Producer Responsibility) exposure uncertainty that could trigger unquantified liability under pharmaceutical waste management rules. Non-compliance with SEBI BRSR Core Expansion disclosure mandates exposes the company to enforcement action and potential delisting risk, particularly material given its ₹462.8 crore revenue base. The absence of reported Scope 1 and 2 emissions data—despite operating a manufacturing facility—suggests incomplete GHG accounting rather than genuine zero emissions, representing a regulatory red flag under BRSR P6 environmental disclosures that could trigger scrutiny and reputational costs. Immediate priority: establish baseline emissions inventory, clarify EPR applicability and associated contingent liabilities, and implement BRSR disclosure compliance infrastructure to mitigate regulatory and market access risks.

Source: Syncom Formulations (India) Limited BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.

← Back to ESG Quotient Dashboard Share on LinkedIn Browse all companies →